The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

[1]  G. Francis,et al.  Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study , 2022, The Lancet.

[2]  E. Fabris,et al.  Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice , 2021, American Journal of Cardiovascular Drugs.

[3]  R. Rosenson.  Existing and emerging therapies for the treatment of familial hypercholesterolemia , 2021, Journal of lipid research.

[4]  D. Rader,et al.  ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report , 2021, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Tom R. Gaunt,et al.  ANNALS EXPRESS: Establishing reference intervals for triglyceride containing lipoprotein sub-fraction metabolites measured using Nuclear Magnetic Resonance Spectroscopy in a UK population. , 2020, Annals of clinical biochemistry.

[6]  D. Gaudet,et al.  Evinacumab for Homozygous Familial Hypercholesterolemia. , 2020, The New England journal of medicine.

[7]  Jonathan C. Cohen,et al.  Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance , 2020, Journal of Lipid Research.

[8]  D. Gaudet,et al.  Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[10]  L. Tokgozoglu,et al.  Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry). , 2019, Journal of clinical lipidology.

[11]  R. Hegele,et al.  Lipid-Lowering Agents. , 2019, Circulation research.

[12]  M. Doumas,et al.  Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. , 2019, Current pharmaceutical design.

[13]  L. Donini,et al.  Metabolomic signature of angiopoietin-like protein 3 deficiency in fasting and postprandial state , 2018, bioRxiv.

[14]  F. Raal,et al.  Familial hypercholesterolemia treatments: Guidelines and new therapies. , 2018, Atherosclerosis.

[15]  R. Santos.  Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia: Connecting the Dots. , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[16]  M. Davidson,et al.  PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. , 2018, Reviews in cardiovascular medicine.

[17]  J. Tu,et al.  Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis , 2017, BMJ Open.

[18]  R. Hegele,et al.  Lomitapide for the treatment of hypercholesterolemia , 2017, Expert opinion on pharmacotherapy.

[19]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[20]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[21]  J. Danesh,et al.  ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. , 2017, Journal of the American College of Cardiology.

[22]  C. Shoulders,et al.  HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. , 2016, Atherosclerosis.

[23]  R. Nordyke,et al.  Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia , 2016, Journal of the American Heart Association.

[24]  A. Rodday,et al.  Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES) , 2016, Circulation.

[25]  M. Jauhiainen,et al.  The role of ANGPTL3 in controlling lipoprotein metabolism , 2016, Endocrine.

[26]  J. Mckenney,et al.  Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy , 2015, Journal of the American Heart Association.

[27]  G. Watts,et al.  Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia , 2015, Drugs.

[28]  Jonathan C. Cohen,et al.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys1[S] , 2015, Journal of Lipid Research.

[29]  E. Bruckert.  Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement. , 2014, Atherosclerosis. Supplements.

[30]  J. Borén,et al.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[31]  R. Rosenson,et al.  Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values , 2013, Cardiovascular Drugs and Therapy.

[32]  M. McGowan.  Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis. , 2013, Journal of clinical lipidology.

[33]  D. Gaudet,et al.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study , 2013, The Lancet.

[34]  Samia Mora,et al.  Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. , 2011, Journal of clinical lipidology.

[35]  Jonathan C. Cohen,et al.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.

[36]  W. Cromwell,et al.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.

[37]  M. Matsuda,et al.  Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[38]  C. Fraser,et al.  Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. , 2005, Endocrinology.

[39]  A. Jenkins,et al.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.

[40]  F. Raal,et al.  Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[41]  P. Duell,et al.  Low-Density Lipoprotein (LDL) Apheresis , 2015 .

[42]  Yosuke Ando,et al.  Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. , 2006, Experimental animals.